Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)

Página do item simplificado
dc.contributor.authorTonello, Matheus
dc.contributor.authorCosta, Rogerio A.
dc.contributor.authorAlmeida, Felipe P. P.
dc.contributor.authorBarbosa, Jose C. [UNESP]
dc.contributor.authorScott, Ingrid U.
dc.contributor.authorJorge, Rodrigo
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionAraraquara Eye Hosp Hosp Olhos Araraquara
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionPenn State Coll Med
dc.date.accessioned2014-05-20T15:32:50Z
dc.date.available2014-05-20T15:32:50Z
dc.date.issued2008-06-01
dc.description.abstractPurpose: To evaluate the effects of panretinal photocoagulation (PRP) compared with PRP plus intravitreal bevacizumab on best corrected visual acuity (BCVA) and total area of fluorescein leakage from active new vessels (NVs) in patients with high-risk proliferative diabetic retinopathy (PDR).Methods: We carried out a prospective study of patients with high-risk PDR and no prior laser treatment who were randomly assigned to receive PRP (PRP group) or PRP plus intravitreal injection of 1.5 mg of bevacizumab (PRP-plus group). In all patients, the PRP was administered at two time-points (weeks 1 and 3), with the intravitreal bevacizumab delivered at the end of the second laser episode in the PRP-plus group. Standardized ophthalmic evaluation including Early Treatment Diabetic Retinopathy Study BCVA as well as stereoscopic fundus photography and fluorescein angiography were performed at baseline and at weeks 4, 9 (+/- 1) and 16 (+/- 2). Main outcome measures included changes in BCVA and in total area of fluorescein leakage from active NVs.Results: Twenty-two (n = 30 eyes) consecutive patients completed the 16-week follow-up. There was no significant difference between the PRP and PRP-plus groups with respect to age, gender, type or duration of diabetes, area of fluorescein leakage from active NVs or BCVA. No significant difference in BCVA was observed between the groups throughout the study period. However, the total area of actively leaking NVs was significantly reduced in the PRP-plus group compared with the PRP group at weeks 4, 9 and 16 (p < 0.001). No major adverse events were identified.Conclusions: In the short-term, the adjunctive use of intravitreal bevacizumab with PRP was associated with a greater reduction in the area of active leaking NVs than PRP alone in patients with high-risk PDR.en
dc.description.affiliationUniv São Paulo, Dept Ophthalmol, São Paulo, Brazil
dc.description.affiliationAraraquara Eye Hosp Hosp Olhos Araraquara, Macular Imaging & Treatment Div UDAT, São Paulo, Brazil
dc.description.affiliationUniv Estadual Paulista, São Paulo State Univ, Exact Sci Dept, São Paulo, Brazil
dc.description.affiliationPenn State Coll Med, Dept Ophthalmol, Hershey, PA USA
dc.description.affiliationPenn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA
dc.description.affiliationUnespUniv Estadual Paulista, São Paulo State Univ, Exact Sci Dept, São Paulo, Brazil
dc.format.extent385-389
dc.identifierhttp://dx.doi.org/10.1111/j.1600-0420.2007.01056.x
dc.identifier.citationActa Ophthalmologica. Oxford: Blackwell Publishing, v. 86, n. 4, p. 385-389, 2008.
dc.identifier.doi10.1111/j.1600-0420.2007.01056.x
dc.identifier.issn1755-375X
dc.identifier.lattes1664688357804299
dc.identifier.urihttp://hdl.handle.net/11449/41625
dc.identifier.wosWOS:000256496800006
dc.language.isoeng
dc.publisherBlackwell Publishing
dc.relation.ispartofActa Ophthalmologica
dc.relation.ispartofjcr3.324
dc.rights.accessRightsAcesso aberto
dc.sourceWeb of Science
dc.subjectangiogenesisen
dc.subjectdiabetesen
dc.subjectlaseren
dc.subjecttreatmenten
dc.subjectvascular endothelial growth factoren
dc.titlePanretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)en
dc.typeArtigo
dcterms.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dcterms.rightsHolderBlackwell Publishing
unesp.author.lattes1664688357804299
unesp.campusUniversidade Estadual Paulista (Unesp), Instituto de Ciência e Tecnologia, São José dos Campospt

Arquivos

Licença do Pacote
Agora exibindo 1 - 2 de 2
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Biociências e Diagnóstico Bucal - ICT